Jung, Su Young
Yug, Ji Seob
Clarke, Jeffery M.
Bauer, Todd M.
Keedy, Vicki L.
Hwang, Sunjin
Kim, Seong-Jin
Chung, Eun Kyoung
Lee, Jangik I. http://orcid.org/0000-0002-5565-8323
Funding for this research was provided by:
MedPacto Inc
Article History
Received: 21 June 2019
Accepted: 17 October 2019
First Online: 30 October 2019
Compliance with ethical standards
:
: JIL and EKC have received research funding from MedPacto, Inc. JMC, TMB and VLK received grant from MedPacto, Inc. for conduct of the phase 1 clinical trial as principal investigators. JMC has received research grant as a principal investigator from Bristol-Myers Squibb, Eli Lilly, Genentech, Spectrum, Adaptimmune, MedPacto, Bayer, AbbVie, and Moderna, and served as an advisory consultant for AstraZeneca, Guardant, Merck and Eli Lilly. TMB has received research grant from Daiichi Sankyo, Incyte, Mirati Therapeutics, MedImmune, Abbvie, AstraZeneca, Merck, Eli Lilly, GlaxoSmithKline, Novartis, Genentech, Deciphera, Merrimack, Immunogen, Millennium, Roche, Aileron Therapeutics, Bristol-Myers Squibb, Amgen, Onyx, Sanofi, Boehringer-Ingelheim, Astellas Pharma, Janssen, Clovis Oncology, Takeda, Karyopharm Therapeutics, Foundation Medicine, and ARMO Biosciences. VLK is a consultant for Karyopharm Therapeutics, and has research funding from Plexxicon, Eli Lilly, Daiichi Sankyo, BioMed Valley Discoveries, Immune Design, GlaxoSmithKline, TRACON Pharma, and Advenchen Laboratories. SJK has a personal financial interest as a shareholder in MedPacto, Inc. SH is an employee of MedPacto, Inc. Other remaining authors have nothing to disclose.
: All procedures involving human participants performed in this study were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards.
: Informed consent was obtained from all individual participants included in the study.